Study Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’snews2024-05-06T16:19:15+00:00May 6th, 2024|The New York Times|
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Mostnews2023-12-08T22:46:17+00:00December 8th, 2023|The New York Times|
Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approvalnews2023-11-16T22:23:56+00:00November 16th, 2023|The New York Times|
A New Sickle Cell Treatment Will Change Lives — but How Many?news2023-10-30T09:01:12+00:00October 30th, 2023|The New York Times|
FDA Approves Biogen’s Drug for Rare Form of ALSnews2023-04-25T17:53:59+00:00April 25th, 2023|The New York Times|
A Dilemma for Governments: How to Pay for Million-Dollar Therapiesnews2023-01-25T00:27:17+00:00January 25th, 2023|The New York Times|
They Created a Drug for Susannah. What About Millions of Other Patients?news2022-12-19T22:40:09+00:00December 19th, 2022|The New York Times|
Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trialnews2022-12-02T21:55:07+00:00December 2nd, 2022|The New York Times|
The Disease Took Zara, Then Sara. Could Ayla Be Saved?news2022-11-09T22:00:17+00:00November 9th, 2022|The New York Times|
Gene Treatment for Rare Epilepsy Causes Brain Side Effect in 2 Childrennews2022-10-26T18:19:16+00:00October 26th, 2022|The New York Times|
